Travere Therapeutics (TVTX) Tops Q4 EPS by 31c

Travere Therapeutics (NASDAQ: TVTX) reported Q4 EPS of ($0.76), $0.31 better than the analyst estimate of ($1.07). Revenue for the quarter came in at $52.3 million versus the consensus estimate of $56.99 million.

For earnings history and earnings-related data on Travere Therapeutics (TVTX) click here.

You May Also Be Interested In

• TJX stock drops as profit outlook falls short of analyst estimates
• Lowe's slashes full-year sales outlook amid DIY spending pressure
• Ameramex International, Inc. (AMMX) Reports In-Line Q2 EPS